PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the installation of the first EOS system at a hospital in the Dallas-Fort Worth area. This installation marks the second medical facility in Texas to adopt low dose 2D/3D imaging achieved with the EOS system. The Company also announced its participation at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, taking place March 24-28 in Las Vegas, where it will launch its newly released hipEOS surgical planning software.
The newly installed EOS system will serve pediatric and adult patients in the Dallas-Fort Worth area suffering from spinal deformities and degenerative spine, hip and knee conditions.
Dr. Isador Lieberman, M.D., M.B.A., FRCSC of the Texas Back Institute said, “As an orthopedic surgeon my goal is to provide the most appropriate and least invasive care to improve the condition and quality of life of the patients with whom I work. I am thrilled that local patients now have access to the unique benefits of the EOS system, which reduces the radiation dose during imaging sessions while also providing clinically superior diagnostic results.”
Marie Meynadier, CEO of EOS imaging, said, “We are pleased that a key orthopedic center in the Dallas-Fort Worth area has selected EOS imaging to support its leadership position in orthopedics. This installation demonstrates the growing interest in the U.S. for low dose 2D/3D orthopedic imaging as the adoption of EOS continues to increase throughout the region and the country.”
In addition to the adoption of the EOS system in Texas, EOS imaging has a robust agenda at AAOS 2015, where the Company will exhibit and host an educational symposium to support the official launch of hipEOS in the U.S. AAOS is the largest international orthopedic meeting, attracting more than 14,000 domestic and international orthopedic surgeons and healthcare providers.
The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA (As Low As Reasonably Available) principle by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.
EOS imaging Exhibition Booth# 5222 at AAOS | March 24-28, 2015: Visitors are invited to learn more about the EOS technology, view live hipEOS demonstrations and discover how the software can help surgeons perform pre-surgical planning using EOS’ unique stereo-radiographic 2D/3D low dose images.
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: annual results for 2014 and turnover for the 1st quarter of 2015: on April 20, 2015 (after market).
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.
